search
Back to results

Trial of Iseganan in Prevention of Ventilator-Associated Pneumonia

Primary Purpose

Pneumonia

Status
Terminated
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
iseganan hydrochloride
Sponsored by
IntraBiotics Pharmaceuticals
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional prevention trial for Pneumonia focused on measuring ventilator-associated pneumonia, VAP, pneumonia, ICU infection

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Greater than or equal to 18 years of age Orally/nasally intubated and receiving mechanical ventilation for <24 hours prior to scheduled randomization and administration of the first dose of Study Drug, and in the judgment of the attending physician, expected to remain intubated and mechanically ventilated for at least 48 hours Expected to survive for at least 21 days and to remain at the investigational site and not transferred to another institution while intubated during the 21-day study period Willing and able to provide written informed consent, or if unconscious or have altered sensorium, have a surrogate provide written informed consent as approved by the institution Negative pregnancy test within 7 days prior to randomization if a female of childbearing potential (Negative pregnancy test results [urine or serum] obtained for reason other than the purposes of this study are acceptable.) Exclusion Criteria: Current diagnosis of pneumonia (Patients currently receiving antibiotics for treatment of pneumonia and patients who meet the study definition of clinically defined pneumonia at the time of screening will be excluded.) Absolute neutrophil count less than 1000/mm3 Human immunodeficiency virus infection with a last known CD4 count less than 500/mm3 Recipient of organ transplantation and receiving immunosuppressive therapy Current hematologic malignancy Previously documented cystic fibrosis Severe cranio-facial trauma or other medical condition expected to require imminent tracheostomy Patient, patient's family and/or physician not in favor of aggressive medical management or presence of an advanced directive to withhold life-sustaining treatment Moribund state or expected to survive less than 21 days due to an uncorrectable medical condition Participation in a clinical trial of any unlicensed drug, biologic or device within 30 days prior to the first dose of study drug Concurrent participation in a clinical trial of any unlicensed drug, biologic or device.

Sites / Locations

  • Barnes-Jewish Hospital

Outcomes

Primary Outcome Measures

The primary objectives of this trial are to evaluate the safety and efficacy of iseganan when administered to intubated patients receiving mechanical ventilation.

Secondary Outcome Measures

The secondary objectives of this trial are to compare patients receiving iseganan to patients receiving placebo on the following: VAP-free survival through Day 21
Days alive and free of parenteral antibiotic use through Day 14
Days alive and free of mechanical ventilation through Day 14

Full Information

First Posted
July 1, 2005
Last Updated
July 11, 2005
Sponsor
IntraBiotics Pharmaceuticals
search

1. Study Identification

Unique Protocol Identification Number
NCT00118781
Brief Title
Trial of Iseganan in Prevention of Ventilator-Associated Pneumonia
Official Title
Randomized, Double-Blind, Placebo-Controlled, Multinational Phase 3 Trial Of Iseganan In Prevention Of Ventilator-Associated Pneumonia
Study Type
Interventional

2. Study Status

Record Verification Date
July 2005
Overall Recruitment Status
Terminated
Study Start Date
September 2003 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
June 2004 (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
IntraBiotics Pharmaceuticals

4. Oversight

5. Study Description

Brief Summary
This is a multinational, double-blind, placebo-controlled trial designed to assess whether iseganan, applied topically to the oral cavity, can prevent ventilator-associated pneumonia among patients who are intubated and mechanically ventilated and survive for up to 14 days.
Detailed Description
Patients will be randomized and receive their first dose of Study Drug within 24 hours of oral/nasal intubation and the initiation of mechanical ventilation. The Study Period will begin with the first administration of Study Drug (Study Day 1). Three mL of Study Drug (9 mg iseganan or matching placebo) will be applied to all visible surfaces in the oral cavity and the oral portion of the endotracheal tube (for non-tracheostomy patients) every 4 hours through Study Day 14, or until the diagnosis of microbiologically-confirmed pneumonia (based on central laboratory results) or extubation, whichever occurs first. All patients will be evaluated for clinically defined pneumonia at least once daily and, if diagnosed, blood specimens will be collected and cultured, and a bronchoscopic alveolar lavage (BAL) specimen (for intubated patients) or a respiratory secretion specimen (for extubated patients) will be obtained PRIOR to initiating or changing any systemic antimicrobial therapy.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pneumonia
Keywords
ventilator-associated pneumonia, VAP, pneumonia, ICU infection

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 2, Phase 3
Interventional Study Model
Single Group Assignment
Masking
Double
Allocation
Randomized
Enrollment
900 (false)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
iseganan hydrochloride
Primary Outcome Measure Information:
Title
The primary objectives of this trial are to evaluate the safety and efficacy of iseganan when administered to intubated patients receiving mechanical ventilation.
Secondary Outcome Measure Information:
Title
The secondary objectives of this trial are to compare patients receiving iseganan to patients receiving placebo on the following: VAP-free survival through Day 21
Title
Days alive and free of parenteral antibiotic use through Day 14
Title
Days alive and free of mechanical ventilation through Day 14

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Greater than or equal to 18 years of age Orally/nasally intubated and receiving mechanical ventilation for <24 hours prior to scheduled randomization and administration of the first dose of Study Drug, and in the judgment of the attending physician, expected to remain intubated and mechanically ventilated for at least 48 hours Expected to survive for at least 21 days and to remain at the investigational site and not transferred to another institution while intubated during the 21-day study period Willing and able to provide written informed consent, or if unconscious or have altered sensorium, have a surrogate provide written informed consent as approved by the institution Negative pregnancy test within 7 days prior to randomization if a female of childbearing potential (Negative pregnancy test results [urine or serum] obtained for reason other than the purposes of this study are acceptable.) Exclusion Criteria: Current diagnosis of pneumonia (Patients currently receiving antibiotics for treatment of pneumonia and patients who meet the study definition of clinically defined pneumonia at the time of screening will be excluded.) Absolute neutrophil count less than 1000/mm3 Human immunodeficiency virus infection with a last known CD4 count less than 500/mm3 Recipient of organ transplantation and receiving immunosuppressive therapy Current hematologic malignancy Previously documented cystic fibrosis Severe cranio-facial trauma or other medical condition expected to require imminent tracheostomy Patient, patient's family and/or physician not in favor of aggressive medical management or presence of an advanced directive to withhold life-sustaining treatment Moribund state or expected to survive less than 21 days due to an uncorrectable medical condition Participation in a clinical trial of any unlicensed drug, biologic or device within 30 days prior to the first dose of study drug Concurrent participation in a clinical trial of any unlicensed drug, biologic or device.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Marin Kollef, MD
Organizational Affiliation
Barnes-Jewish Hospital, Washington University School of Medicine
Official's Role
Study Chair
Facility Information:
Facility Name
Barnes-Jewish Hospital
City
St. Louis
State/Province
Missouri
ZIP/Postal Code
63110
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Trial of Iseganan in Prevention of Ventilator-Associated Pneumonia

We'll reach out to this number within 24 hrs